Bionomics Ltd (ASX:BNO) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Bionomics requested the halt pending details regarding results from its BNC210 Phase 2 clinical trial in patients with Generalised Anxiety Disorder.
The halt will remain in place until the opening of trade on Wednesday 21st September 2016, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.